Globus Medical, Inc. $GMED Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC raised its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 37.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 102,132 shares of the medical device company’s stock after buying an additional 27,971 shares during the quarter. Intech Investment Management LLC owned approximately 0.08% of Globus Medical worth $7,650,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of GMED. Janus Henderson Group PLC increased its holdings in shares of Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after buying an additional 328,217 shares during the last quarter. Sculptor Capital LP raised its position in Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Dimensional Fund Advisors LP raised its position in Globus Medical by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Globus Medical by 14.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock valued at $133,731,000 after purchasing an additional 225,534 shares during the last quarter. Finally, Boston Trust Walden Corp lifted its stake in shares of Globus Medical by 4.4% in the 3rd quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock valued at $123,071,000 after purchasing an additional 69,782 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In other Globus Medical news, Director Ann D. Rhoads sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares in the company, valued at $3,007,640. The trade was a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James Tobin sold 41,666 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the sale, the director directly owned 15,000 shares in the company, valued at $1,127,400. This represents a 73.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 76,666 shares of company stock worth $5,794,017. 18.38% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GMED has been the subject of a number of research analyst reports. Truist Financial lowered their price objective on shares of Globus Medical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Monday, November 9th. UBS Group began coverage on Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price on the stock. Wells Fargo & Company upped their price target on Globus Medical from $99.00 to $100.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Needham & Company LLC lowered their price target on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, November 6th. Finally, Wall Street Zen lowered Globus Medical from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and a consensus price target of $96.08.

Read Our Latest Stock Analysis on GMED

Globus Medical Stock Performance

Shares of GMED opened at $70.14 on Wednesday. The stock has a market capitalization of $9.29 billion, a PE ratio of 17.23, a P/E/G ratio of 1.09 and a beta of 0.98. Globus Medical, Inc. has a 1 year low of $69.49 and a 1 year high of $101.40. The company’s 50-day simple moving average is $76.31 and its 200-day simple moving average is $82.50.

Globus Medical (NYSE:GMED – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03. The business had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts predict that Globus Medical, Inc. will post 4.98 earnings per share for the current year.

Globus Medical Profile

(Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Further Reading

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.